All Stories

  1. Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis

    Article • The Lancet Infectious Diseases, December 2025, Elsevier

    Nana Kiria

  2. Cost-effectiveness of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis in Belarus, Georgia, Kazakhstan and the Republic of Moldova

    Article • BMJ Global Health, November 2025, BMJ

    Nana Kiria

  3. Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study

    Article • The Lancet Regional Health - Europe, September 2025, Elsevier

    Professor JEROME ROBERT, Nana Kiria

  4. Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2025, New England Journal of Medicine (NEJM/MMS)

    Nana Kiria

  5. The Frequency and Incidence of QT Prolongation With Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country Multidrug-Resistant/Rifampicin-Resistant Tuberculosis Cohort

    Article • Clinical Infectious Diseases, December 2024, Oxford University Press (OUP)

    Nana Kiria

  6. Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial

    Article • The Lancet Respiratory Medicine, December 2024, Elsevier

    Nana Kiria

  7. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study

    Article • The Lancet Infectious Diseases, October 2024, Elsevier

    Nana Kiria

  8. Closure of TB pulmonary cavern using endobronchial valve placement

    Article • Oxford Medical Case Reports, March 2024, Oxford University Press (OUP)

    Nana Kiria

  9. Nine-month, all-oral regimens for rifampin-resistant tuberculosis

    Article • January 2024, openRxiv

    Nana Kiria

  10. Programmatic management of bedaquiline-pretomanid-linezolid regimens in Georgia.

    Article • September 2023, European Respiratory Society (ERS)

    Nana Kiria

  11. Study of Moxifloxacin and Silver Nanoparticle Composite Efficacy on pre-XDR Mycobacterium Tuberculosis Strains

    Article • September 2023, European Respiratory Society (ERS)

    Nana Kiria

  12. Usage of Silver Nanoparticles to Restore Rifampicin Efficacy for Rifampicin-Resistant M.Tuberculosis Cultures

    Article • September 2023, European Respiratory Society (ERS)

    Nana Kiria

  13. Tuberculosis recovery in Georgia: implementing more by 24

    Article • The Lancet Infectious Diseases, August 2023, Elsevier

    Nana Kiria

  14. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

    Article • The Lancet, November 2022, Elsevier

    Nana Kiria

  15. Study of rifampicin and silver nanoparticle composite efficacy on rifampicin-resistant Mycobacterium tuberculosis strains

    Article • September 2022, European Respiratory Society (ERS)

    Nana Kiria

  16. Usage of silver nanoparticles to restore Moxifloxacin efficacy for fluoroquinolone-resistant M.tuberculosis cultures.

    Article • September 2022, European Respiratory Society (ERS)

    Nana Kiria

  17. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines

    Article • BMJ Open, December 2021, BMJ

    Nana Kiria

  18. Screening for tuberculosis in patients with COVID-19 infection in Georgia

    Article • September 2021, European Respiratory Society (ERS)

    Nana Kiria

  19. Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020

    Article • Monaldi Archives for Chest Disease, January 2021, PAGEPress Publications

    Nana Kiria

  20. Trends in tuberculosis notification and treatment in Georgia

    Article • September 2020, European Respiratory Society (ERS)

    Nana Kiria

  21. Linezolid use for drug-resistant tuberculosis in Georgia: a retrospective cohort study

    Article • The International Journal of Tuberculosis and Lung Disease, April 2020, International Union Against Tuberculosis and Lung Disease

    Nana Kiria

  22. The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis

    Article • September 2019, European Respiratory Society (ERS)

    Nana Kiria

  23. Experience of treatment Pre-XDR and XDR-TB/HIV co-infection with bedaquiline and delamanid containing regimens in Georgia

    Article • September 2018, European Respiratory Society (ERS)

    Nana Kiria

  24. Implementation of FAST strategy in the National Center for Tuberculosis and Lung Diseases (NCTLD) in Georgia

    Article • September 2018, European Respiratory Society (ERS)

    Nana Kiria

  25. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia

    Article • The International Journal of Tuberculosis and Lung Disease, July 2018, International Union Against Tuberculosis and Lung Disease

    Nana Kiria

  26. Normalization of Epigenetic Change in the Genome by Peptide Bioregulator (Ala–Glu–Asp–Gly) in Pulmonary Tuberculosis

    Article • International Journal of Peptide Research and Therapeutics, March 2018, Springer Science + Business Media

    Nana Kiria

  27. Treatment of DR-TB in penitential system of Georgia with new TB-medications

    Article • September 2017, European Respiratory Society (ERS)

    Nana Kiria

  28. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries

    Article • The International Journal of Tuberculosis and Lung Disease, February 2017, International Union Against Tuberculosis and Lung Disease

    Professor JEROME ROBERT, Nana Kiria

  29. Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations

    Article • American Review of Respiratory Disease, October 2016, American Thoracic Society

    Nana Kiria

  30. Steps of bedaquline implementation in Georgia

    Article • September 2016, European Respiratory Society (ERS)

    Nana Kiria

  31. Influence of the trigger technique on ventricular function measurements using 3-Tesla magnetic resonance imaging: comparison of ECG versus pulse wave triggering

    Article • Acta Radiologica, May 2011, SAGE Publications

    Nana Kiria